ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

anagliptin

Also written as “Anagliptin” and “SK-0403”.

Its studies are mostly in Diabetes Mellitus, Type 2, led by 3 companies.

Drug pageAnagliptin: every studyAll 7 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jan 21, 20266 company-led studies, 1 open or runningNext primary completion: Mar 31, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
JW Pharmaceutical31 open or runningphase 4since Jan 21, 2026Feb 6, 2012Mar 31, 2027phase 4 · NCT07442006
Kowaits history only20 open or runningphase 2since Jul 22, 2010May 25, 2010none ahead
Sanwa Kagaku Kenkyushoits history only10 open or runningphase 2since Sep 19, 2007Sep 19, 2007none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of JW Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 6, 2012First studies: 2 phase 3 studies in Diabetes Mellitus, Type 2First studyNCT01529541, NCT01529528
  2. Jan 21, 2026Phase 4 study in Diabetes Mellitus, Type 2NCT07442006 · 178 planned · South Korea

Ahead

  1. Mar 31, 2027Primary completion: phase 4 study in Diabetes Mellitus, Type 2NCT07442006

TargetBeta

DPP4 →read by rule
“An orally available, potent, selective inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity”NCIt, by rule
“Dipeptidyl peptidase IV inhibitor”ChEMBL 37, by rule

Other programs on DPP4

ProgramCompanyFurthest phaseStudies
sitagliptinruleMerckphase 4123
LinagliptinruleBoehringer Ingelheimphase 496
gemigliptinruleLG Chemphase 430
Empagliflozin/LinagliptinruleHumanis Saglık Anonim Sirketiphase 12
cofrogliptinruleHaisco Pharmaceutical Groupno phase1

Studies

All 3 JW Pharmaceutical leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07442006Diabetes Mellitus, Type 2 · South Korea4RecruitingMar 31, 2027178
NCT01529541Diabetes Mellitus, Type 2 · Korea, Republic of3CompletedMay 2013200
NCT01529528Diabetes Mellitus, Type 2 · South Korea3CompletedSep 2012117

How it is read

Names in the registry

  • “Anagliptin”, 4 entries
  • “SK-0403”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.